Inability or unwillingness to swallow pillsXx_NEWLINE_xXAbility to swallow entrectinib intactXx_NEWLINE_xXUnable or unwilling to swallow napabucasin capsules daily.Xx_NEWLINE_xXThe subject has a gastrointestinal disease that would prevent him or her from being able to swallow or absorb flucytosineXx_NEWLINE_xXPatients must be able to swallow capsulesXx_NEWLINE_xXPatients unable to swallow capsules whole are not eligible; nasogastric or gastric (G) tube administration is not allowedXx_NEWLINE_xXMust be able to swallow pillsXx_NEWLINE_xXPatients must be able to swallow whole capsulesXx_NEWLINE_xXPatients must be able to swallow pillsXx_NEWLINE_xXPatients must be able to swallow intact capsulesXx_NEWLINE_xXSubjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:\r\n* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills\r\n* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel\r\n* Active peptic ulcer disease\r\n* Malabsorption syndromeXx_NEWLINE_xXPatients must be able to swallow intact capsulesXx_NEWLINE_xXInability or unwillingness to swallow pillsXx_NEWLINE_xXPatients must be able to swallow pills and must not have malabsorption problems or ongoing nausea and vomiting that would affect oral treatmentXx_NEWLINE_xXAble to swallow capsulesXx_NEWLINE_xXInability to swallow capsules or known gastrointestinal malabsorptionXx_NEWLINE_xXAble to swallow ribociclib capsulesXx_NEWLINE_xXInability or unwillingness to swallow pillsXx_NEWLINE_xXPatient must be able to swallow capsulesXx_NEWLINE_xXSubjects who are unable to swallow pillsXx_NEWLINE_xXSubject must be able to swallow solid dosage forms.Xx_NEWLINE_xXAble to swallow capsulesXx_NEWLINE_xXInability or unwillingness to swallow capsules; patients with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:\r\n* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills;\r\n* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel;\r\n* Active peptic ulcer disease;\r\n* Malabsorption syndromeXx_NEWLINE_xXAble to swallow capsulesXx_NEWLINE_xXSubjects must be able to swallow whole capsule.Xx_NEWLINE_xXThe subject is unable to swallow capsules.Xx_NEWLINE_xXPatient must be able to swallow pills wholeXx_NEWLINE_xXAbility to swallow pills or capsulesXx_NEWLINE_xXSubject is able to swallow pills.Xx_NEWLINE_xXInability to swallow capsulesXx_NEWLINE_xXSubject is unable to swallow pillsXx_NEWLINE_xXAbility to swallow the study drug as a whole tabletXx_NEWLINE_xXInability to swallow gelatin capsules, or any medical condition that interferes with normal gastrointestinal absorptionXx_NEWLINE_xXThe ability to swallow pills and otherwise follow the protocolXx_NEWLINE_xXParticipant must be able to swallow pillsXx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXPatients must be able to swallow capsules; nasogastric or gastrostomy feeding (G) tube administration is not allowedXx_NEWLINE_xXUnable or unwilling to swallow napabucasin capsules daily.Xx_NEWLINE_xXInability or unwillingness to swallow whole pillsXx_NEWLINE_xXParticipant is able to swallow a tablet wholeXx_NEWLINE_xXInability to swallow pills;Xx_NEWLINE_xXAbility to swallow the study drugsXx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXAbility to swallow pills/capsulesXx_NEWLINE_xXInability to swallow capsules, since capsules cannot be crushed or brokenXx_NEWLINE_xXPatients must be able to swallow capsulesXx_NEWLINE_xXPatient must be able to swallow capsulesXx_NEWLINE_xXAre able to swallow capsulesXx_NEWLINE_xXAble to swallow the study drug(s) whole as a tabletXx_NEWLINE_xXUnable to swallow capsules or disease significantly affecting gastrointestinal functionXx_NEWLINE_xXAbility to swallow the study drug as a whole tablet.Xx_NEWLINE_xXAble to swallow the study drug whole as a tabletXx_NEWLINE_xXCOHORT 3: ENDOMETRIAL CANCER: Patients must be able to swallow oral medications (capsules) without chewing, breaking, crushing, opening or otherwise altering the product formulationXx_NEWLINE_xXPatients must be able to swallow intact capsulesXx_NEWLINE_xXPatients must be able to swallow capsulesXx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXAre able to swallow capsules.Xx_NEWLINE_xXFor Combination Therapy cohort only: Able to swallow pills.Xx_NEWLINE_xXPatient must be able to swallow capsule or tabletXx_NEWLINE_xXUnable to swallow or take anything orallyXx_NEWLINE_xXAble to swallow the study drug whole as a tablet.Xx_NEWLINE_xXAble to swallow study drugs whole as a tablet/capsule.Xx_NEWLINE_xXInability or unwillingness to swallow pillsXx_NEWLINE_xXPatients must be able to swallow whole pillsXx_NEWLINE_xXMust be able to swallow pillsXx_NEWLINE_xXMen unable to swallow pillsXx_NEWLINE_xXPatients who are unable to swallow pillsXx_NEWLINE_xXAble to swallow study drugXx_NEWLINE_xXAble to swallow intact capsulesXx_NEWLINE_xXInability to swallow capsules, since capsules cannot be crushed or brokenXx_NEWLINE_xXThe subject is unable to swallow capsulesXx_NEWLINE_xXPatient must be able to swallow pillsXx_NEWLINE_xXInability or unwillingness to swallow pills.Xx_NEWLINE_xXMust be able to swallow ribociclib (LEE-011) tablet/capsuleXx_NEWLINE_xXParticipants must be able to swallow oral pillsXx_NEWLINE_xXMust be able to swallow pills or capsulesXx_NEWLINE_xXPatient is not able to swallow pillsXx_NEWLINE_xXAbility to swallow capsules unless enrolled in Part EXx_NEWLINE_xXPart E: Any patient unable to swallow capsules who otherwise meet all other eligibility criteria for Part A (expansion) B, C or DXx_NEWLINE_xXPatients must be able to swallow whole capsules; nasogastric or gastrointestinal (G)-tube administration is not allowedXx_NEWLINE_xXAble to swallow capsulesXx_NEWLINE_xXAny condition that impairs patient‘s ability to swallow whole pillsXx_NEWLINE_xXPatients must be able to swallow AZD1775 capsulesXx_NEWLINE_xXAbility to swallow and retain capsules.Xx_NEWLINE_xXPatient must be able to swallow pillsXx_NEWLINE_xXPatients must be able to swallow pillsXx_NEWLINE_xXPHASE II: Patients must be able to swallow pillsXx_NEWLINE_xXPatients who are unable to swallow pills or who have undergone surgery that prohibits the absorption of pills in the stomachXx_NEWLINE_xXAble to swallow the study drugs wholeXx_NEWLINE_xXAbility to swallow capsulesXx_NEWLINE_xXInability to swallow capsules, since capsules cannot be crushed or brokenXx_NEWLINE_xXPART 2 GROUP 1 INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsulesXx_NEWLINE_xXPART 2 GROUP 2A INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsulesXx_NEWLINE_xXPART 2 GROUP 3 INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsulesXx_NEWLINE_xXAble to swallow the study drugs whole as a tabletXx_NEWLINE_xXAble to swallow study drugs whole as a tablet/capsuleXx_NEWLINE_xXAbility to swallow pillsXx_NEWLINE_xXAbility to swallow pills, or liquid formulation and for patient or parent/legal guardian to keep an accurate medication recordXx_NEWLINE_xXPatients unable to swallow pills.Xx_NEWLINE_xXThe subject must be able to swallow ribociclib (LEE011)Xx_NEWLINE_xXImpaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallow up to five ceritinib capsules daily; although, patients unable to swallow capsules will be allowed to participate in this study, by following the specific instructions on making a slurry of the medicationXx_NEWLINE_xXPatients who are unable to swallow pills/capsules are ineligibleXx_NEWLINE_xXPatients must be able to swallow intact capsules wholeXx_NEWLINE_xXAble to swallow pillsXx_NEWLINE_xXPatient must be able to swallow capsulesXx_NEWLINE_xXAbility to swallow pills or capsulesXx_NEWLINE_xXMust be able to swallow pills.Xx_NEWLINE_xXInability or unwillingness to swallow capsulesXx_NEWLINE_xXUnable to swallow capsulesXx_NEWLINE_xXUnable to swallow medicationXx_NEWLINE_xXPatients with malabsorption syndrome or other condition that would interfere with intestinal absorption; patients must be able to swallow capsulesXx_NEWLINE_xXAble to swallow pillsXx_NEWLINE_xXPatients unable or unwilling to swallow pillsXx_NEWLINE_xXPatients must have the ability to swallow pillsXx_NEWLINE_xXUnable to swallow medication or suspected malabsorptionXx_NEWLINE_xXPatient must be able to swallow pillsXx_NEWLINE_xXAny condition that impairs patient‘s ability to swallow whole pillsXx_NEWLINE_xXMust be able to swallow pillsXx_NEWLINE_xXPatient must be able to swallow capsulesXx_NEWLINE_xXCapacity to swallowXx_NEWLINE_xXAbility to swallow pillsXx_NEWLINE_xXLack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to swallow pills.Xx_NEWLINE_xXPatients who are unable to swallow pillsXx_NEWLINE_xXInability or unwillingness to swallow pills.Xx_NEWLINE_xXPatients who are unable to swallow oral gel capsules are not eligibleXx_NEWLINE_xXAble to swallow capsules, with no surgical or anatomic condition that will preclude the patient from swallowing and absorbing oral medicationsXx_NEWLINE_xXAbility to swallow medication capsules by mouth (which may include taking nilotinib mixed in apple sauce)Xx_NEWLINE_xXParticipants must be able to swallow capsulesXx_NEWLINE_xXAble to swallow capsules whole (pomalidomide capsules cannot be crushed, dissolved or broken)Xx_NEWLINE_xXPatients must be able to swallow whole capsulesXx_NEWLINE_xXPatients must be able to swallow capsulesXx_NEWLINE_xXPatient must be able to swallow capsulesXx_NEWLINE_xXAble to swallow and absorb the medicationXx_NEWLINE_xXPatients must be able to swallow pillsXx_NEWLINE_xXParticipants must be able and willing to swallow pills and to absorb oral medicationsXx_NEWLINE_xXInability to swallow lenalidomide capsules whole; capsules of 13-isotretinoin may be openedXx_NEWLINE_xXWillingness and ability to swallow study drugsXx_NEWLINE_xXPatients must be able to swallow capsulesXx_NEWLINE_xXPatient must be able to swallow capsules and have no surgical or anatomic condition that will preclude the patient from swallowing and absorbing oral medications on an ongoing basisXx_NEWLINE_xXMust be able to swallow ribociclib capsulesXx_NEWLINE_xXSubject is able to swallow capsules and is able to take or tolerate oral medications on a continuous basisXx_NEWLINE_xXPatients must be able to swallow capsules wholeXx_NEWLINE_xXPHASE II: Patients must be able to swallow capsules wholeXx_NEWLINE_xXKnown inability to swallow capsulesXx_NEWLINE_xXPatients must be able to swallow whole capsulesXx_NEWLINE_xXPatients must be able to swallow capsules wholeXx_NEWLINE_xXPatients who are unable to swallow pillsXx_NEWLINE_xXPatients must be able to swallow the drugXx_NEWLINE_xXPatients must be able to swallow pillsXx_NEWLINE_xXPatients who are unable to swallow pills are excludedXx_NEWLINE_xXPatient must be able to swallow pillsXx_NEWLINE_xXPHASE II: Patient must be able to swallow pillsXx_NEWLINE_xXPart C: Patients must be able to swallow intact capsulesXx_NEWLINE_xXSubjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:\r\n* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills\r\n* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel\r\n* Active peptic ulcer disease\r\n* Malabsorption syndromeXx_NEWLINE_xXPatient must be able to swallow pillsXx_NEWLINE_xXPatients must be able to swallow whole capsules and tolerate oral medicationsXx_NEWLINE_xXPatients unable to swallow whole capsulesXx_NEWLINE_xXAny condition that impairs the patient’s ability to swallow whole pillsXx_NEWLINE_xXAble to swallow whole capsulesXx_NEWLINE_xXPatient must be able to swallow pillsXx_NEWLINE_xXPatients taking the capsule formulation must be able to swallow capsules; feeding tube administration is allowed for patients receiving the oral solution (OS)Xx_NEWLINE_xXPatients must be able to take oral medications; patients must be able to swallow capsules whole without crushing or altering them in any wayXx_NEWLINE_xXare able to swallow capsulesXx_NEWLINE_xXPatient must be able to swallow pills and have no significant impairment in gastrointestinal absorption including history of gastric bypass surgeryXx_NEWLINE_xXUnable to swallow pillsXx_NEWLINE_xXPatients must be able to swallow whole capsulesXx_NEWLINE_xXInability to swallow capsules.Xx_NEWLINE_xXUnable to swallow capsules or disease significantly affecting gastrointestinal functionXx_NEWLINE_xXPatients must be able to swallow whole capsulesXx_NEWLINE_xXSubject is able to swallow capsulesXx_NEWLINE_xXPatients must be able to swallow whole capsuleXx_NEWLINE_xXUnable to swallow capsules or disease significantly affecting gastrointestinal functionXx_NEWLINE_xXUnable or unwilling to swallow BBI608 and/or BBI503 capsules dailyXx_NEWLINE_xXUnable or unwilling to swallow BBI608 capsules daily.Xx_NEWLINE_xXSubject cannot reliably swallow pillsXx_NEWLINE_xXMust be able to swallow lenalidomide capsulesXx_NEWLINE_xXRequires total parenteral nutrition and is unable to swallow pills or unable to take a suspension through a gastrostomy tubeXx_NEWLINE_xXUnable or unwilling to swallow BBI608 capsules dailyXx_NEWLINE_xXAre able to swallow capsulesXx_NEWLINE_xXUnable to swallow capsulesXx_NEWLINE_xXPatients must be able to swallow capsulesXx_NEWLINE_xXParticipant must be able to swallow pillsXx_NEWLINE_xXInability to swallow capsulesXx_NEWLINE_xXParticipant must be able to swallow pillsXx_NEWLINE_xXPatients must be able to swallow whole capsulesXx_NEWLINE_xXInability to swallow capsules.Xx_NEWLINE_xXAble to swallow pillsXx_NEWLINE_xXPatients who cannot swallow pillsXx_NEWLINE_xXInability or unwillingness to swallow pillsXx_NEWLINE_xXAble to swallow the study drug as a whole tabletXx_NEWLINE_xXAble to swallow pillsXx_NEWLINE_xXPatient must be able to swallow capsule or tabletXx_NEWLINE_xXAble to swallow thin liquids or have a feeding tube for delivery of nutritionXx_NEWLINE_xXWillingness to swallow pills and no medical condition that would interfere with thisXx_NEWLINE_xXAny condition that impairs patient‘s ability to swallow whole pillsXx_NEWLINE_xXAble to swallow the study drug whole as a tabletXx_NEWLINE_xXUnable or unwilling to swallow BBI608 capsules daily.Xx_NEWLINE_xXAble to swallow capsulesXx_NEWLINE_xXMust be able to swallow whole pillsXx_NEWLINE_xXAble to swallow the study drug whole as a tabletXx_NEWLINE_xXPatients must have the ability to swallow the study drug whole as a tablet or capsuleXx_NEWLINE_xXAbility to swallow liquidsXx_NEWLINE_xXAble to swallow the study drug whole as a tabletXx_NEWLINE_xXAny condition that impairs patient‘s ability to swallow whole pills; patients with feeding tubes, intractable nausea or vomiting, or a malabsorption syndrome are not eligibleXx_NEWLINE_xXAny condition that impairs patient's ability to swallow whole pillsXx_NEWLINE_xXPatient must be able to swallow pillsXx_NEWLINE_xXAble to swallow the study drug whole as a tabletXx_NEWLINE_xXUnable or unwilling to swallow BBI503 capsules dailyXx_NEWLINE_xXUnable or unwilling to swallow BBI608 capsules daily.Xx_NEWLINE_xXAble to swallow the study drug whole as a tabletXx_NEWLINE_xXAble to swallow and absorb the medicationXx_NEWLINE_xXAbility to swallow pills and keep medication recordXx_NEWLINE_xXThe ability to swallow pillsXx_NEWLINE_xXInability to take oral medications on a continuous basis; patients who are to take pazopanib, sorafenib, or sunitinib and are unable to swallow pills whole are ineligible (the pills cannot be crushed or broken)Xx_NEWLINE_xXPatients who are unable to swallow pillsXx_NEWLINE_xXPatients who cannot swallow capsulesXx_NEWLINE_xXPatients who are unable to swallow pills are not eligibleXx_NEWLINE_xXPatients must be able to swallow intact capsulesXx_NEWLINE_xXInability to swallow capsules or known gastrointestinal malabsorptionXx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXUnable to swallow pillsXx_NEWLINE_xXSubjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:\r\n* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills\r\n* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel\r\n* Active peptic ulcer disease, not on a proton pump inhibitor\r\n* Malabsorption syndromeXx_NEWLINE_xXPatients must be able to safely swallow pills.Xx_NEWLINE_xXAbility to swallow oral capsulesXx_NEWLINE_xXAre able to swallow capsulesXx_NEWLINE_xXPatient must be able to swallow capsules and has no surgical or anatomical condition that will preclude the patient from swallowing and absorbing oral medications on an ongoing basisXx_NEWLINE_xXPatients must be able to swallow pillsXx_NEWLINE_xXUnable or unwilling to swallow the complete daily dose of ARQ 087 capsulesXx_NEWLINE_xXPatient must be able to swallow pillsXx_NEWLINE_xXUnable to swallow medicationXx_NEWLINE_xXUnable to swallow medication; suspected malabsorptionXx_NEWLINE_xXPatients must be able to swallow the vorinostat capsules or have a feeding tube to allow for drug suspensionXx_NEWLINE_xXAny condition that impairs patient’s ability to swallow pills will make patient ineligibleXx_NEWLINE_xXAble to swallow medicationXx_NEWLINE_xXInability to swallow the HKI-272 capsulesXx_NEWLINE_xXAble to swallow capsulesXx_NEWLINE_xXPatient must be able to swallow pillsXx_NEWLINE_xXPatients must be able to swallow whole pillsXx_NEWLINE_xXAble to swallow capsulesXx_NEWLINE_xXInability to swallow capsulesXx_NEWLINE_xXAble to swallow the study drugs whole.Xx_NEWLINE_xXAble to swallow pillsXx_NEWLINE_xXSubject must be able to swallow medicationXx_NEWLINE_xXParticipants must be able to swallow pills to participate in the studyXx_NEWLINE_xXPatients must be able to swallow whole capsules; capsules must not be crushed or chewed; capsules must not be openedXx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patient must be able to swallow capsules wholeXx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Patient must be able to swallow capsules wholeXx_NEWLINE_xXKnown inability to swallow up to five ceritinib (LDK378) capsules dailyXx_NEWLINE_xXInability or unwillingness to swallow pillsXx_NEWLINE_xXAbility to swallow the study drugs whole.Xx_NEWLINE_xXECOG PS (Eastern Cooperative Group Performance Status) of 0 or 1. 8. Ability to swallow oral capsules without difficulty. 9. Pregnancy Prevention Risk Management Plan:Xx_NEWLINE_xXInability to swallow oral capsulesXx_NEWLINE_xXInability or unwillingness to swallow capsulesXx_NEWLINE_xXInability or unwillingness to swallow pillsXx_NEWLINE_xXAble to swallow capsules and maintain adequate hydrationXx_NEWLINE_xXPatients will be excluded if they are unable to swallow capsules whole.Xx_NEWLINE_xXUnable to swallow a whole tablet or capsule.Xx_NEWLINE_xXMust be able to swallow whole capsulesXx_NEWLINE_xXUnable or unwilling to swallow BBI608/placebo capsules daily.Xx_NEWLINE_xXPatients must be able to swallow capsulesXx_NEWLINE_xXDoes the subject have any gastrointestinal disease that would prevent him or her from being able to swallow or absorb flucytosine?Xx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXInability or unwillingness to swallow capsulesXx_NEWLINE_xXAbility to swallow study drug whole as a capsuleXx_NEWLINE_xXPatients must be able to swallow whole capsulesXx_NEWLINE_xXPHASE II: >= 2 and =< 18 years; body surface area (BSA) >= 0.55 m^2, and able to swallow whole capsulesXx_NEWLINE_xXInability to swallow capsules, since capsules cannot be crushed or brokenXx_NEWLINE_xXPatients with malabsorption syndrome or other condition that would interfere with intestinal absorption of pills; patients must be able to swallow pillsXx_NEWLINE_xXAble to swallow the study drug whole as a tabletXx_NEWLINE_xXAny condition that severely impairs patient’s ability to swallow whole pillsXx_NEWLINE_xXAbility to swallow capsules, with the exception of head and neck squamous cell carcinoma participants who may have study drug crushed and administered through a feeding tubeXx_NEWLINE_xXAny condition that impairs patient‘s ability to swallow whole pillsXx_NEWLINE_xXAny condition that impairs patient‘s ability to swallow whole pillsXx_NEWLINE_xXAny condition that impairs patient‘s ability to swallow whole pillsXx_NEWLINE_xXPatients must be able to swallow pillsXx_NEWLINE_xXPatients must be able to swallow capsules whole; nasogastric or gastrostomy (G) tube administration is not allowedXx_NEWLINE_xXPatients must be able to swallow pills and have no significant impairment in gastrointestinal absorptionXx_NEWLINE_xXAble to swallow pillsXx_NEWLINE_xXAbility to swallow the study drugsXx_NEWLINE_xXAble to swallow whole capsulesXx_NEWLINE_xXPatients must be able to swallow capsulesXx_NEWLINE_xXInability or unwillingness to swallow pillsXx_NEWLINE_xXSubject is able to swallow enzalutamide capsules and comply with study requirements.Xx_NEWLINE_xXPatients must be able to swallow either intact capsules or mini-tabs without chewingXx_NEWLINE_xXAble to swallow the study drug whole as a tabletXx_NEWLINE_xXParticipant must be able to swallow pills (psychology staff will be available to assist with pill swallowing training if needed)Xx_NEWLINE_xXAble to swallow thin liquidsXx_NEWLINE_xXAble to swallow supplementsXx_NEWLINE_xXPatient must have the ability to swallow multiple capsulesXx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXParticipants who are unable to swallow pillsXx_NEWLINE_xXAble to swallow capsulesXx_NEWLINE_xXAble to swallow oral capsules without difficulty.Xx_NEWLINE_xXPatients must be able to swallow pillsXx_NEWLINE_xXAble to swallow capsulesXx_NEWLINE_xXAble to swallow medicationXx_NEWLINE_xXSubjects that are unable to swallow a tablet/pill for any reasonXx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXPatient must be able to swallow capsules (phase III only)Xx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXParticipant must be able to swallow pillsXx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXInability or unwillingness to swallow capsulesXx_NEWLINE_xXPatients must be able to swallow whole capsulesXx_NEWLINE_xXPatients must be able to swallow pillsXx_NEWLINE_xXUnable or unwilling to swallow BBI608 capsules dailyXx_NEWLINE_xXMale or female subjects ? 21 years-of-age with the demonstrated ability to swallow capsules whole and who are willing to provide access to previously obtained biopsy resultsXx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXSubjects that are unable to swallow a tablet/pillXx_NEWLINE_xXUnable to swallow orally administered medication whole.Xx_NEWLINE_xXAble to swallow pillsXx_NEWLINE_xXPatient is able to swallow a capsuleXx_NEWLINE_xXInability to swallow pillsXx_NEWLINE_xXAbility to swallow pillsXx_NEWLINE_xXBe able to swallow medicationXx_NEWLINE_xXInability or unwillingness to swallow pillsXx_NEWLINE_xXUnable to swallow capsules or disease significantly affecting gastrointestinal functionXx_NEWLINE_xX